背景:我们的目的是研究HALP评分是否是胶质母细胞瘤(GBM)患者生存的预测因子。
方法:本研究纳入了我们诊所随访的84例胶质母细胞瘤(GBM)患者。使用术前血红蛋白计算HALP评分,白蛋白,患者的淋巴细胞和血小板结果。对于HALP分数,通过检查受试者工作特征(ROC)曲线下的面积,发现了截止值.根据该临界值将患者分为低和高两组。临床之间的关系,使用这两组检查了患者的皮肤图和实验室参数。
结果:操作系统中位数,PFS,HALP得分,NLR,PLR为15个月(1.0-78.0),8个月(1.0-66.0),37.39±23.84(最小6.00-最大132.31),分别为4.14、145.07。HALP评分与OS之间存在统计学上显著的相关性,PFS,NLR,PLR,ECOG-PS状态采用Spearman’srho检验(分别为p=0.001,p<0.001,p<0.001,p<0.001,p=0.026)。对于HALP分数,使用ROC分析发现截断值=37.39(AUC=0.698,95%CI,p<0.002)。低HALP组的中位OS为12个月(6.99-17.01),高HALP组的中位OS为21个月(11.37-30.63)(p=0.117)。HALP高组的NLR和PLR显著降低(分别为p<0.001,p<0.001)。高HALP组接收医治的比例显著增高(p<0.05)。在多变量分析中,发现治疗状态和ECOG-PS状态有显著结果(分别为p<0.001,p=0.038).
结论:治疗开始时测量的HALP评分似乎对GBM患者的预后具有预测意义。>37.39的HALP评分与高级别脑肿瘤的生存期延长相关。
BACKGROUND: We aimed to investigate whether the HALP score was a predictor of survival in patients with Glioblastoma (GBM).
METHODS: A total of 84 Glioblastoma (GBM) patients followed in our clinic were included in the study. HALP scores were calculated using the preoperative hemoglobin, albumin, lymphocyte and platelet results of the patients. For the HALP score, a cut-off value was found by examining the area below the receiver operating characteristic (ROC) curve. Patients were divided into two groups as low and high according to this cut-off value. The relationships among the clinical, dermographic and laboratory parameters of the patients were examined using these two groups.
RESULTS: Median OS, PFS, HALP score, NLR, PLR were 15 months (1.0-78.0), 8 months (1.0-66.0), 37.39 ± 23.84 (min 6.00-max 132.31), 4.14, 145.07 respectively. A statistically significant correlation was found between HALP score and OS, PFS, NLR, PLR, ECOG-PS status using Spearman\'s rho test (p = 0.001, p < 0.001, p < 0.001, p < 0.001, p = 0.026 respectively). For the HALP score, a cut-off value of = 37.39 (AUC = 0.698, 95% CI, p < 0.002) was found using ROC analysis. Median OS was 12 (6.99-17.01) months in the low HALP group and 21 (11.37-30.63) months in the high HALP group (p = 0.117). NLR and PLR were significantly lower in the HALP high group (p < 0.001, p < 0.001 respectively). The ratio of receiving treatment was significantly higher in the high HALP group (p < 0.05). In Multivariate analysis, significant results were found for treatment status and ECOG-PS status (p < 0.001, p = 0.038 respectively).
CONCLUSIONS: The HALP score measured at the beginning of treatment seems to have predictive importance in the prognosis of GBM patients. A HALP score of > 37.39 was associated with prolonged survival in high-grade brain tumors.